Shun Yamamoto

944 total citations
79 papers, 604 citations indexed

About

Shun Yamamoto is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shun Yamamoto has authored 79 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Surgery, 46 papers in Oncology and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shun Yamamoto's work include Esophageal Cancer Research and Treatment (53 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Gastric Cancer Management and Outcomes (34 papers). Shun Yamamoto is often cited by papers focused on Esophageal Cancer Research and Treatment (53 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Gastric Cancer Management and Outcomes (34 papers). Shun Yamamoto collaborates with scholars based in Japan, United States and United Kingdom. Shun Yamamoto's co-authors include Ken Kato, Satoshi Fujita, Yoshihiro Moriya, Takayuki Akasu, Kengo Nagashima, Yoshitaka Honma, Narikazu Boku, Natsuko Okita, Atsuo Takashima and Hiroyuki Daiko and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.

In The Last Decade

Shun Yamamoto

64 papers receiving 594 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shun Yamamoto Japan 14 338 323 269 72 62 79 604
Osamu Shiraishi Japan 17 708 2.1× 251 0.8× 613 2.3× 90 1.3× 112 1.8× 84 1.0k
Hajime Yokomizo Japan 12 241 0.7× 282 0.9× 129 0.5× 30 0.4× 59 1.0× 121 512
Junhai Pan China 9 158 0.5× 286 0.9× 276 1.0× 104 1.4× 100 1.6× 23 532
Mao-Chih Hsieh Taiwan 16 342 1.0× 181 0.6× 453 1.7× 216 3.0× 69 1.1× 29 752
C. Ross Carter United Kingdom 10 302 0.9× 351 1.1× 172 0.6× 63 0.9× 89 1.4× 15 604
J-L. van Laethem Belgium 8 265 0.8× 254 0.8× 132 0.5× 70 1.0× 72 1.2× 14 520
Yong Fang China 12 143 0.4× 124 0.4× 208 0.8× 101 1.4× 49 0.8× 41 400
Shria Kumar United States 11 321 0.9× 143 0.4× 205 0.8× 69 1.0× 64 1.0× 51 475
Weidong Xiao China 17 383 1.1× 401 1.2× 331 1.2× 43 0.6× 97 1.6× 51 664
Yingbo Chen China 15 222 0.7× 147 0.5× 363 1.3× 109 1.5× 89 1.4× 26 533

Countries citing papers authored by Shun Yamamoto

Since Specialization
Citations

This map shows the geographic impact of Shun Yamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shun Yamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shun Yamamoto more than expected).

Fields of papers citing papers by Shun Yamamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shun Yamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shun Yamamoto. The network helps show where Shun Yamamoto may publish in the future.

Co-authorship network of co-authors of Shun Yamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Shun Yamamoto. A scholar is included among the top collaborators of Shun Yamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shun Yamamoto. Shun Yamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamamoto, Shun, et al.. (2025). Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma. Future Oncology. 21(12). 1473–1481.
2.
Cooper, Zachary A., Ying Wang, Rakesh Kumar, et al.. (2025). Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma. Discover Oncology. 16(1). 427–427.
3.
4.
5.
Yamamoto, Shun, Yoshitaka Honma, Hidekazu Hirano, et al.. (2024). Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin. In Vivo. 38(2). 761–766. 2 indexed citations
6.
Yamamoto, Shun, Ken Kato, Hiroyuki Daiko, et al.. (2024). Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502. Future Oncology. 20(36). 2849–2854. 1 indexed citations
7.
Abe, Seiichiro, Satoru Nonaka, Haruhisa Suzuki, et al.. (2024). Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy. Diseases of the Esophagus. 37(5). 2 indexed citations
8.
9.
Iwasa, Satoru, Kengo Nagashima, Shun Yamamoto, et al.. (2023). Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab. Cancer Medicine. 12(8). 9322–9331. 2 indexed citations
10.
Yamamoto, Shun, Satoru Matsuda, Motoo Nomura, et al.. (2023). Rare malignant neoplasm of the esophagus: current status and future perspectives. Japanese Journal of Clinical Oncology. 54(2). 111–120. 8 indexed citations
11.
Yamamoto, Shun, Chin‐Yo Lin, F. Rivera Herrero, et al.. (2023). 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology. 34. S1548–S1548. 1 indexed citations
12.
13.
Yamamoto, Shun, et al.. (2023). Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future Oncology. 20(11). 665–677. 1 indexed citations
14.
Yamamoto, Shun, et al.. (2022). Pembrolizumab for the treatment of advanced esophageal cancer. Future Oncology. 18(18). 2311–2319. 6 indexed citations
15.
Yamamoto, Shun, Yoshitaka Honma, Junya Oguma, et al.. (2022). Efficacy of prophylactic pegfilgrastim on day three of preoperative DCF chemotherapy in elderly patients with resectable esophageal cancer.. Journal of Clinical Oncology. 40(4_suppl). 305–305. 2 indexed citations
16.
Shoji, Hirokazu, Hidekazu Hirano, Koji Izutsu, et al.. (2021). Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer. Case Reports in Oncology. 14(1). 85–89.
17.
Yamamoto, Shun, Kengo Nagashima, Takeshi Kawakami, et al.. (2021). Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer. 21(1). 1159–1159. 1 indexed citations
18.
Yamamoto, Shun & Ken Kato. (2020). Immuno-Oncology for Esophageal Cancer. Future Oncology. 16(32). 2673–2681. 19 indexed citations
19.
Yamamoto, Shun, Ken Kato, Hiroyuki Daiko, et al.. (2020). Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E). Future Oncology. 16(19). 1351–1357. 44 indexed citations
20.
Yamamoto, Shun, Hideki Ueno, Midori Tanaka, et al.. (2017). Comparative effectiveness of gemcitabine vs gemcitabine+nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer. Annals of Oncology. 28. ix88–ix88. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Osamu Shiraishi Breakdown of academic impact, for papers by Hajime Yokomizo Breakdown of academic impact, for papers by Junhai Pan Breakdown of academic impact, for papers by Mao-Chih Hsieh Breakdown of academic impact, for papers by C. Ross Carter Breakdown of academic impact, for papers by J-L. van Laethem Breakdown of academic impact, for papers by Yong Fang Breakdown of academic impact, for papers by Shria Kumar Breakdown of academic impact, for papers by Weidong Xiao Breakdown of academic impact, for papers by Yingbo Chen
Rankless by CCL
2026